Although some studies have reported the possible therapeutic role of VEGF inhibitors in women with PCOS [125], the clinical application of anti-VEGF therapy should be cautious before we fully understand the underlying mechanism whereby VEGF influences embryo implantation and the pharmacokinetic characteristics of these drugs. This evidence concerns the gene VEGFA and polycystic ovary syndrome.